Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia 33Leukemia, Myeloid, Acute 31Leukemia, Lymphocytic, Chronic, B-Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 18Lymphoma, Non-Hodgkin 18Lymphoma 17Hodgkin Disease 16Multiple Myeloma 12Lymphoma, Mantle-Cell 11Recurrence 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Burkitt Lymphoma 10Waldenstrom Macroglobulinemia 8Neoplasms, Plasma Cell 8Neoplasm Metastasis 8Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Hematologic Neoplasms 7Congenital Abnormalities 7Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6

Interventions

Pemetrexed 7Cisplatin 7Cyclophosphamide 5pembrolizumab 4fludarabine 4Platinum 3Drug Therapy 3aldesleukin 2Nivolumab 2Ipilimumab 2Interleukin-2 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1regorafenib 1napabucasin 1methoxyamine 1fludarabine phosphate 1enzalutamide 1cediranib 1avelumab 1atezolizumab 1anetumab ravtansine 1Vorinostat 1Thiostrepton 1Tetrahydrouridine 1Radiosurgery 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × fludarabine phosphate × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡